LONG-TERM STABLE MIXED CHIMAERISM FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION FOR SEVERE APLASTIC ANAEMIA

1990 ◽  
Vol 76 (1) ◽  
pp. 146-147 ◽  
Author(s):  
T. R. Spitzer ◽  
E. Himoe ◽  
M. Cottler-Fox ◽  
R. Cahill ◽  
H. J. Deeg
2012 ◽  
Vol 158 (1) ◽  
pp. 120-128 ◽  
Author(s):  
Lauri M. Burroughs ◽  
Ann E. Woolfrey ◽  
Barry E. Storer ◽  
H. Joachim Deeg ◽  
Mary E. D. Flowers ◽  
...  

1989 ◽  
Vol 7 (8) ◽  
pp. 1039-1045 ◽  
Author(s):  
G L Phillips ◽  
D E Reece ◽  
M J Barnett ◽  
J M Connors ◽  
J W Fay ◽  
...  

Eight patients with refractory Hodgkin's disease received intensive combination chemotherapy conditioning with cyclophosphamide, carmustine (BCNU), and etoposide (VP 16-213), and allogeneic marrow transplants. All patients achieved complete responses. Three patients relapsed; two died of Hodgkin's disease and one of chronic graft-v-host disease (GVHD) and infection. In all, four patients died due to transplant-related toxicity. One patient developed a fatal B-cell lymphoproliferative disorder soon after transplantation, and died without evidence of Hodgkin's disease. One patient is alive and free of progression 29 months after transplantation. These data indicate that allogeneic marrow transplantation may be considered as therapy for selected patients with advanced Hodgkin's disease and, despite substantial toxicity, will occasionally result in long-term responses. Better patient selection would likely improve results.


1989 ◽  
Vol 71 (4) ◽  
pp. 525-533 ◽  
Author(s):  
Hélène Keable ◽  
Jean-Henri Bourhis ◽  
Olivier Brison ◽  
Pierre Lehn ◽  
Claudine Schenmetzler ◽  
...  

2004 ◽  
Vol 33 (5) ◽  
pp. 509-517 ◽  
Author(s):  
T K Marras ◽  
C K Chan ◽  
J H Lipton ◽  
H A Messner ◽  
J P Szalai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document